Nasal drug developer Leyden Laboratories announced that former Moderna vaccine development executive Jintanat Ananworanich has joined the company as Chief Medical Officer. Ananworanich was most recently Executive Director of clinical development at Moderna, and her previous experience includes roles as Clinical Development Leader at the Bill and Melinda Gates Medical Research Institute and as Associate Director for HIV Therapeutics Research with the US Military HIV Research Program (MHRP). She is currently a professor at the University of Amsterdam.
In 2021, Leyden Labs announced that it was working with CRO Nanopharm on development of the company’s antiviral nasal sprays. The company announced the initiation of clinical development of its PanFlu intranasal CR9114 anti-hemagglutinin stem human antibody in April 2023.
Leyden Labs CEO Koenraad Wiedhaup commented, “We are very excited to announce the appointment of Dr. Ananworanich as the CMO of Leyden Labs. We are thrilled to add her incredible expertise to the team to further guide the development of our intranasal product candidates.”
Chief Scientific Officer Jaap Goudsmit added, “Dr. Ananworanich brings impressive breadth and immense depth in both clinical and development experience which will be instrumental as we advance our portfolio of intranasal product candidates through the clinic.”
Ananworanich said, “I am honored to join Leyden Labs, a company at the forefront of employing the power of mucosal immunity to protect against known and unknown respiratory viruses. Viruses are responsible for a huge burden of death and disease worldwide, and we need medicines that could provide immediate protection against new viral threats. I am thrilled to join Leyden Labs’ team of experts on the biology of the respiratory mucosa as we work together to free people from the threat of respiratory viruses.”
Read the Leyden Laboratories press release.
